Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CNA3103 |
| Synonyms | |
| Therapy Description |
CNA3103 are T-lymphocytes engineered to express a chimeric antigenic receptor (CAR) targeting LGR5, which potentially decrease tumor growth (Cancer Res (2022) 82 (12_Supplement): 5574). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CNA3103 | CNA3103 are T-lymphocytes engineered to express a chimeric antigenic receptor (CAR) targeting LGR5, which potentially decrease tumor growth (Cancer Res (2022) 82 (12_Supplement): 5574). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05759728 | Phase Ib/II | CNA3103 | A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | Recruiting | AUS | 0 |